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Summary
  Background:  It has been suggested that increased testosterone secretion in postmenopausal obese women mi-
ght have some protective effect on bone tissue; the association might be significantly influenced 
by the RANKL/RANK/OPG system.
  Aim:  The aim of the study was to determine whether postmenopausal obese women showed any rela-
tionship between the pattern of adipose tissue distribution, circadian free testosterone (FT) con-
centrations and bone metabolism (as assessed based on circadian osteocalcin [OC] and C-terminal 
telopeptide [CTx] levels), and to establish whether osteoprotegerin (OPG) and receptor activator 
of nuclear factor-kB ligand (RANKL) might play a role in the relationship.
  Material/Methods:  FT, OC, CTx, OPG and soluble RANKL (sRANKL) levels were determined by ELISA in serum 
samples collected every three hours for 24 hours from 47 postmenopausal women (12 with gy-
noid obesity [GO], 17 with android obesity [AO], and 18 healthy individuals).
  Results:  Obese women demonstrated an adipose tissue distribution-dependent increase in mean circa-
dian FT levels and a decrease in mean circadian OC, CTx, OPG and sRANKL compared to con-
trol participants. In GO subjects, these changes were accompanied by smaller FT amplitudes, 
suppression of the circadian rhythms of bone markers and OPG, and a shift of sRANKL rhythm 
acrophase, whereas AO subjects showed a decrease in bone marker amplitudes and suppression 
of OPG and sRANKL rhythms. In comparison with the controls, significant adipose tissue di-
stribution-dependent changes were found in the correlations between FT and bone markers, FT 
and OPG, OC and CTx, OPG and sRANKL, CTx and OPG, and CTx and sRANKL. Compared 
to GO participants, those with AO had higher coefficients of correlations between mean circa-
dian FT and OC as well as between OC and CTx, and lower in the case of FT and sRANKL as 
well as CTx and OPG and CTx and sRANKL.
    Postmenopausal obesity results in adipose tissue distribution-dependent alterations in circadian 
FT levels accompanied by suppression of bone metabolism and a decline in circadian variations 
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       -               -               -               -               -       Background
Clinical studies have indicated that an increase in obesity 
extent in postmenopausal women is associated with incre-
ased levels of circulating androgens, and not only those of 
adrenal origin [1,13,47]. A significant correlation was fo-
und between body mass and body mass index (BMI), and 
circadian levels of total and free testosterone (T and FT) 
and/or bone metabolism in obese postmenopausal women 
[1,26,28,33,37,41]. A relationship was also observed betwe-
en the general pattern of adipose tissue distribution in wo-
men and bone mineral density (BMD); the latter was pro-
ved higher in android obesity [12,39]. Android obesity in 
women is believed to reduce sex hormone-binding globulin 
(SHBG) thus increasing the amount of FT [35,36,43,44], 
which, in turn, may affect bone metabolism. In vitro studies 
have indicated that osteokines of the receptor activator of 
nuclear factor-kB ligand/receptor activator of the nuclear 
of the osteokines under investigation, especially sRANKL. Increased FT secretion in postmeno-
pausal women might exert a protective effect on bone tissue, most likely via a shift in the OPG/
RANKL ratio that tilts the balance toward a functional excess of OPG.
  Key words:	 free	testosterone	•	bone	metabolism	•	OPG	•	sRANKL	•	obesity	•	menopause
Streszczenie
  Wstęp:  Istnieją sugestie, że zwiększone wytwarzanie testosteronu u otyłych kobiet po menopauzie może 
wpływać ochronnie na tkankę kostną, a istotną rolę w mechanizmie tych zależności pełni naj-
prawdopodobniej system RANKL/RANK/OPG.
  Cel:  Celem pracy było wykazanie, czy u otyłych kobiet po menopauzie istnieje związek między ty-
pem rozmieszczenia tkanki tłuszczowej a okołodobowymi stężeniami wolnego testosteronu (FT) 
i metabolizmem kostnym (ocenianym na podstawie okołodobowych stężeń OC i CTx) oraz usta-
lenie, czy OPG i RANKL mogą mieć znaczenie w mechanizmie tych zależności.
 Materiał/Metody:  U 47 kobiet po menopauzie (12 z otyłością gynoidalną – OG, 17 z otyłością androidalną – OA 
i 18 zdrowych z prawidłową masą ciała) oznaczono metodą ELISA stężenia FT, OC, CTx, OPG 
i sRANKL w surowicy krwi pobieranej w odstępach trzygodzinnych w ciągu doby.
  Wyniki:  U otyłych kobiet wykazano zależny od rozmieszczenia tkanki tłuszczowej wzrost średniodobo-
wych stężeń FT oraz obniżenie średniodobowych stężeń OC, CTx, OPG i sRANKL w porówna-
niu z kontrolą. Zmianom tym u kobiet z OG towarzyszyło obniżenie amplitudy rytmu FT, stłu-
mienie rytmu markerów kostnych i OPG oraz przesunięcie akrofazy rytmu sRANKL, a u kobiet 
z OA zmniejszenie amplitudy rytmu markerów kostnych oraz stłumienie rytmu OPG i sRANKL. 
U otyłych kobiet po menopauzie stwierdzono istotne, zależne od rozmieszczenia tkanki tłuszczo-
wej zmiany powiązań średniodobowych stężeń: FT z markerami kostnymi i OPG, OC z CTx, OPG 
i sRANKL oraz CTx z OPG i sRANKL w odniesieniu do grupy kontrolnej. U kobiet z OA uzy-
skano wyższe wartości współczynników korelacji niż u kobiet z OG w przypadku zależności śred-
niodobowych stężeń: FT z OC oraz OC z CTx, a niższe w przypadku zależności FT z sRANKL 
oraz CTx z OPG i sRANKL.
  Dyskusja/Wnioski:  Otyłość u kobiet po menopauzie wywołuje zależne od rozmieszczenia tkanki tłuszczowej zmia-
ny w okołodobowych stężeniach FT, którym towarzyszy supresja metabolizmu kostnego i około-
dobowych oscylacji badanych osteokin, zwłaszcza sRANKL. Zwiększone wytwarzanie FT u po-
menopauzalnych otyłych kobiet może wpływać ochronnie na tkankę kostną, najprawdopodobniej 
poprzez przesunięcie relacji OPG do sRANKL na korzyść OPG.
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       -               -               -               -               -       factor-kB/osteoprotegerin system (RANKL/RANK/OPG), 
an essential signaling pathway by which osteoblasts control 
the pool of active osteoclasts and thereby bone resorption, 
might be involved in the effect of testosterone on the bone 
[5,7,13,22]. Testosterone has been reported to inhibit, thro-
ugh specific receptors, parathyroid hormone (PTH) stimula-
ted osteoclast differentiation in cultured murine bone cells 
[7]. It also increases the OPG/RANKL ratio (in mouse bo-
ne-cell cultures and the osteoblastic cell line MC3T3-E1) 
through stimulation of OPG mRNA expression, but does 
not affect RANKL mRNA expression [5]. Other authors 
believe that testosterone increases the OPG/RANKL ratio 
via the inhibition of RANKL mRNA expression [7,19]. 
The above-mentioned data seem to suggest that the FT 
increase observed in obese women, and especially those 
with android obesity, might act as a protective factor aga-
inst postmenopausal bone loss.
It should be emphasized that the investigations into fac-
tors affecting bone status, previously performed in obese 
pre- and postmenopausal women, mainly relied on single 
determinations thereof made in the morning hours [28]. 
Since the levels of FT, OPG, sRANKL and bone markers 
are subject to circadian variations [28,29,30,31,32,33], 
it seemed well justified to examine the chronobiological 
aspects of their rhythmicity.
The aim of the study was to determine whether postme-
nopausal obese women demonstrated any relationship be-
tween the pattern of adipose tissue distribution, circadian 
FT concentrations and bone metabolism (as assessed ba-
sed on circadian osteocalcin [OC] and C-terminal telopep-
tide of type I collagen alpha 1 chain [CTx]), and to esta-
blish whether OPG and RANKL might play a role in the 
relationship.
Material and Methods
The investigations were carried out in 29 postmenopausal 
obese women hospitalized in the Endocrinology Division, 
Department of Pathophysiology and Endocrinology of the 
Medical University of Silesia in Zabrze. After exclusion of 
hormonal causes, the patients were diagnosed with simple 
obesity. The study group comprised women with a gyno-
id (lower body) distribution of body fat (GO; waist to hip 
ratio circumference [WHR] <0.8, n=12) and android (up-
per body) distribution of body fat (AO; WHR ≥0.8, n=17) 
whose baseline biochemical parameters were not sugge-
stive of insulin resistance, abnormal lipid profile or glu-
cose tolerance test. The following exclusion criteria were 
applied: liver and kidney failure, coronary heart disease, 
arterial hypertension, diabetes, systemic connective tis-
sue disorders, neoplastic and autoimmune disease, thyro-
id hormone or steroid therapy (estrogen/progestin therapy) 
and nonsteroidal anti-inflammatory agents. Women rece-
iving antiresorptive or immunosuppressive therapy were 
also excluded. Age of onset of obesity was ≥30 years. The 
control group consisted of 18 postmenopausal women with 
normal body weight.
All study participants had an intravenous cannula inser-
ted into the cubital vein. 5-ml blood samples were collec-
ted every three hours for 24 hours (at 08.00, 11.00, 14.00, 
17.00, 20.00, 23.00, 02.00 and 05.00 hours). Serum samples 
obtained by centrifugation were frozen and stored at –75°C 
until analysis.
Serum FT (DRG Instruments GmbH, Germany), OC (DSL 
Inc., USA), CTx (Serum CrossLaps – IDS Inc., USA), OPG 
and sRANKL (BIOMEDICA, Austria) were determined 
by ELISA. Fasting serum samples were also assayed for 
17b estradiol (E2) using RIA (ORION DIAGNOSTICA, 
Finland), and follicle-stimulating hormone (FSH) using 
IRMA test kits (ORION DIAGNOSTICA, Finland). The 
method sensitivity and intra- and interassay errors were as 
follows: FT 0.007 pmol/l, 6.4 and 8%; OC 0.05 µmol/l, 5.8 
and 7.3%; CTx 0.08 nmol/l, 5.2 and 6.7%; OPG 0.14 pmo-
l/l, 7 and 7.5%; sRANKL 0.04 pmol/l, 4.0 and 7.5%, E2 5 
pmol/l, 2.8 and 5.8%; FSH 1 U/l, 2.3 and 4.2%.
All subjects gave their informed consent to participa-
te in the study; the research adhered to the tenets of the 
Declaration of Helsinki.
The project was approved by the Bioethics Committee of 
the Medical University of Silesia (NN-013-240/03 and 
NN-013-24/I/03/04).
The obtained results of FT, OC, CTx, OPG and sRANKL 
determinations were subjected to routine statistical analy-
sis; the level of significance was set at p≤0.05. Circadian 
rhythms were assessed using the cosinor method of Halberg 
et al. [14].
results
Significant differences in body mass, BMI and WHR were 
found between postmenopausal obese women and control 
subjects with normal body weight (Table 1).
Figures 1-5 present the results of circadian FT, bone mar-
kers and osteokines of the RANKL/RANK/OPG system 
determinations in the sera of postmenopausal women with 
gynoid obesity (GO), android obesity (AO) and age-mat-
ched healthy controls (C).
Cosinor analysis revealed a circadian rhythm for FT, with 
acrophases at 9.09, 11.13 and 10.43 hours in the control, 
GO, and AO subjects, respectively. AO subjects exhibited 
a significant increase of FT mesor (mean circadian level) 
when compared to GO and control participants as well as a 
significant decline in circadian FT rhythm amplitude com-
pared to the control. GO participants had greater differen-
ces in the amplitude of FT circadian rhythmicity than tho-
se with AO in comparison with the control group (Fig. 1).
The analysis also indicated a circadian rhythm for OC in 
control and AO participants, with peaks at 3.28 and 1.31 
hours, respectively, whereas GO subjects showed suppres-
sion of circadian OC rhythm. Mean circadian OC levels 
as well as amplitude of OC circadian rhythmicity were si-
gnificantly decreased in both obese subgroups compared 
to the control. GO participants had greater differences in 
the amplitude of OC circadian rhythmicity than those with 
AO in comparison with control subjects (Fig. 2).
The cosinor method validated a significant circadian rhy-
thm of CTx in AO and control participants with acrophases 
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       -               -               -               -               -       at 3.27 and 1.42 hours, respectively. Compared to the con-
trol, both obese subgroups showed similar decreases in 
circadian CTx levels and variations of the marker ampli-
tudes in comparison with the control group. GO subjects 
also showed suppression of circadian CTx rhythm (Fig. 3).
A statistically significant circadian OPG rhythm with 
acrophase at 4.36 was only revealed in the control group. 
Both subgroups of obese women had a significant decre-
ase and of similar magnitude of mean circadian levels of 
the osteokine compared to the control. The amplitudes of 
circadian OPG variations were also smaller in both obese 
Variables
Postmenopausal obese women (n−29) Control group
GO: WHR <0.8
(n-12)
AO: WHR ≥0.8
(n-17)
C: WHR 0.69–0.78
(n-18)
Age (years) 52−65
57.00±7.00
53−63
58.44±4.27
57−62
59.50±3.54
Height (m) 1.52−1.76
1.61±0.12
1.5−1.68
1.59±0.05
1.55−1.68
1.62±0.09
Body mass (kg) 75.60−102.00
87.87±13.30a
69.40−110.70
91.33±12.88a,b
57.00−73.20
65.10±11.46
Body mass index − BMI (kg/m2) 31,11−37,22
33.74±3.14a
31.79−40.80
36.16±3.08a,b
23.75−25.96
24.86±1.56
WHR 0.730.78
0.75±0.03
0.80−0.98
0.87±0.05a,b
0.69−0.78
0.74±0.06
Last menstrual period (age in years) 51−55
53.00±2.82
48−56
51.58±2.11
50−54
52.00±2.82
Time since physiological menopause (years) 4−7
5.50±2.12
3−10
6.50±2.31
4−8
6.00±2.83
Duration of obesity (years) 14−24
19.00±7.07
14−26
18.00±5.66 −
Table 1.  Basic clinical and anthropometric data in postmenopausal obese women with gynoid (GO: WHR <0.8) and android distribution of body fat (AO: 
WHR ≥0.8) and in postmenopausal healthy women with normal body weight (control group – C). The table gives value ranges and arithmetic 
mean ±SD
a p≤0.05 – significant difference vs control group (C); b p≤0.05 – significant difference vs GO group.
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5
4
3
2
1
0
8.00
C
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Groups
C
GO
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Mesor
pmol/l
2.29
2.32
2.57a,b
Amplitude
pmol/l
1.63
1.01a
1.42b
Acrophase
h.min
9.09
11.13
10.43
p
0.006c
0.010c
0.002c
3.74±0.49
2.70±0.59a
3.74±0.42b
4.40±0.76
3.81±0.69a
4.44±0.52b
1.01±0.21
2.70±0.59a
2.43±0.42a
1.04±0.24
1.59±0.48a
1.84±0.38a
3.36±0.24
2.36±0.52a
2.43±0.35a
1.25±0.14
1.21±0.48
1.07±0.31
1.25±0.14
1.56±0.45
1.66±0.31
2.11±0.55
2.50±0.59
2.98±0.49a
11.00 14.00 17.00 20.00 23.00 2.00 5.00
Time of day (hours)
a p≤0.05 – significant differences vs control group; b p≤0.05 – significant differences vs GO group; c statistically signi￿cant circadian rhythm
Fig. 1.  Circadian oscillations of mean serum concentrations of free testosterone (FT; pmol/l ±SD) and chronobiological parameters of FT circadian rhythm 
in postmenopausal obese women with gynoid (GO: WHR <0.8) and android distribution of body fat (AO: WHR ≥0.8)
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       -               -               -               -               -       subgroups; however, the difference was more marked be-
tween AO women and the control than in the case of the 
GO subgroup (Fig. 4).
The analysis revealed a circadian rhythm for sRANKL 
both in the control and GO participants, with acrophases 
at 6.54 and 11.13 hours, respectively. Circadian variations 
of sRANKL levels were disturbed in the obese women. The 
GO subgroup showed a decline in the sRANKL circadian 
mesor, amplitude increase, and acrophase shift towards la-
ter hours. The AO subgroup demonstrated sRANKL rhy-
thm suppression compared to the control; an increase was 
also observed in the mean circadian sRANKL level and 
a decrease in circadian variations amplitude compared to 
GO participants (Fig. 5).
Table 2 presents correlations between mean circa-
dian FT levels, bone markers and osteokines of the 
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6.0
5.5
5.0
4.5
4.0
8.00
C
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C
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µmol/l
5.81
5.24a
5.46a
Amplitude
µmol/l
0.85
1.09a
1.14a,b
Acrophase
h.min
3.28
1.31
p
<0.001c
0.040c
6.14±0.71
5.29±0.58a
5.34±0.45b
5.42±0.68
5.27±0.41
5.36±0.49
5.34±0.69
5.22±0.44
5.35±0.48
5.27±0.60
5.14±0.40
5.40±0.52
3.36±0.24
5.24±0.48a
5.54±0.64a
6.09±0.64
5.31±0.60a
5.57±0.61a
6.70±0.70
5.35±0.52a
5.69±0.64a
4.91±0.52
5.08±0.47
5.40±0.41a
11.00 14.00 17.00 20.00 23.00 2.00 5.00
Time of day (hours)
a p≤0.05 – significant differences vs control group; b p≤0.05 – significant differences vs GO group; c statistically signi￿cant circadian rhythm
abolishing of rhytm
Fig. 2.  Circadian oscillations of mean serum concentrations of osteocalcin (OC; µmol/l ±SD) in serum and chronobiological parameters of OC circadian 
rhythm in postmenopausal obese women with gynoid (GO: WHR <0.8) and android distribution of body fat (AO: WHR ≥0.8)
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p
0.011c
0.031c
5.74±1.98
3.11±1.53a
2.99±1.21a
4.57±2.00
2.10±1.53a
3.29±1.96a,b
2.33±1.19
3.95±0.56a
3.36±2.11
5.74±1.35
2.95±1.21a
3.30±2.04a
8.84±2.54
4.92±0.49
4.81±2.80
7.29±1.89
4.19±0.77a
4.77±2.60a
7.13±2.01
5.23±0.38a
5.28±2.87a
4.11±1.23
3.33±0.44
3.17±1.80
11.00 14.00 17.00 20.00 23.00 2.00 5.00
Time of day (hours)
a p≤0.05 – significant differences vs control group; b p≤0.05 – significant differences vs GO group; c statistically signi￿cant circadian rhythm
abolishing of rhytm
Fig. 3.  Circadian oscillations of mean serum concentrations of C-terminal telopeptide of type I collagen (CTx; nmol/l ±SD) and chronobiological parameters 
of CTx circadian rhythm in postmenopausal obese women with gynoid (GO: WHR <0.8) and android distribution of body fat (AO: WHR ≥0.8)
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       -               -               -               -               -       RANKL/RANK/OPG system in the gynoid and android 
obesity subgroups and controls.
Normal weight postmenopausal women had a significant po-
sitive correlation between mean circadian FT and sRANKL 
as well as OC and CTx. OC and CTx showed a significant 
positive correlation with OPG and sRANKL. OPG corre-
lated positively with sRANKL. The GO subgroup had a si-
gnificant negative correlation between mean circadian FT 
levels and mean circadian CTx. FT also correlated positi-
vely with OPG and sRANKL but the FT/OPG correlation 
coefficient was higher. AO study participants demonstrated 
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a p≤0.05 – significant differences vs control group; b p≤0.05 – significant differences vs GO group; c statistically signi￿cant circadian rhythm
abolishing of rhytm
abolishing of rhytm
Fig. 4.  Circadian oscillations of mean serum concentrations of osteoprotegerin (OPG; pmol/l ±SD) and chronobiological parameters of OPG circadian 
rhythm in postmenopausal obese women with gynoid (GO: WHR <0.8) and android distribution of body fat (AO: WHR ≥0.8)\
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nmol/l
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0.54a
0.65b
Amplitude
nmol/l
0.25
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Acrophase
h.min
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→11.13a
p
0.035c
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0.88±0.016a
0.95±0.105a
0.63±0.048
0.81±0.021a
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0.52±0.083
0.30±0.34a
0.69±0.148a,b
0.79±0.080
0.35±0.012a
0.64±0.128a,b
0.63±0.069
0.32±0.029a
0.61±0.129b
0.76±0.040
0.35±0.024a
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0.51±0.071
0.77±0.122a
0.50±0.031b
11.00 14.00 17.00 20.00 23.00 2.00 5.00
Time of day (hours)
a p≤0.05 – significant differences vs control group; b p≤0.05 – significant differences vs GO group; c statistically signi￿cant circadian rhythm
abolishing of rhytm
Fig. 5.   Circadian oscillations of mean serum concentrations of soluble receptor activator of nuclear factor-κB ligand (sRANKL; pmol/l ±SD) and 
chronobiological parameters of sRANKL circadian rhythm in postmenopausal obese women with gynoid (GO: WHR <0.8) and android distribution 
of body fat (AO: WHR ≥0.8)
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FT levels and mean circadian levels of both bone mar-
kers. FT also correlated positively with OPG. Compared 
to the GO subgroup, a higher correlation coefficient was 
obtained between FT and OC and lower between FT and 
sRANKL. AO women also showed a significant positive 
correlation between mean circadian OC levels and mean 
circadian CTx, whereas GO participants had significant 
positive correlations between mean circadian CTx levels 
and OPG as well as between CTx and sRANKL. In both 
obese subgroups a significant positive correlation was ob-
served between mean circadian OPG and sRANKL levels.
discussion
Obesity is a growing health and social problem, which con-
tributes to the development of serious or even life-threate-
ning diseases including type 2 diabetes, dyslipidemia, arte-
rial hypertension, coronary heart disease, gallstones, sleep 
apnea syndrome, bone and articular diseases and some 
forms of neoplastic disease [43].
Obesity is associated with several endocrine disorders in-
cluding insulin resistance with hyperinsulinemia, sup-
pression of the hypothalamic-pituitary-thyroid axis and 
somatotropic axis, hyperactivity of the hypothalamo-pi-
tuitary-adrenocortical axis, enhanced testosterone secre-
tion and functional androgen excess [35,36]. The distur-
bances are predominant in women with android obesity 
[15,35,36,43].
On the other hand, due to the boost in load on the bone tis-
sue as well as adipose tissue acting as an endocrine gland, 
obesity is more and more frequently considered as protective 
against osteoporosis, and especially in the postmenopausal 
period [6,9,18,21,28,37,38,42]. Healthy but postmenopausal 
obese women have higher BMD of the L2-L4 region, pro-
ximal femoral epiphysis and the radius compared to the-
ir age-matched slim counterparts [9,10,12,21,28,37,38,39]. 
Most authors emphasize a positive correlation between 
BMI and BMD of the L2-L4 region and proximal femo-
ral epiphysis [9,21,28,37]. Postmenopausal obese women 
also demonstrate changes in bone turnover rate compared 
to control subjects. Several determinations of biochemi-
cal bone formation and resorption markers carried out in 
the 1980s [21,28] indicated that obese women might be 
characterized by increased bone formation and/or decre-
ased bone resorption which could lead to bone turnover 
rate decrease, and, consequently, to BMD increase in la-
ter life. However, recent investigations using modern, hi-
ghly sensitive and specific bone markers have revealed 
that an increase in obesity extent is associated with in-
hibition rather than enhancement of bone formation and 
concomitant suppression of bone resorption [6,34,37]. 
Our chronobiological studies seem to confirm the above 
conclusions. We not only found a decrease in mean circa-
dian OC and CTx levels in both obese subgroups compa-
red to the control group, but also statistically significant 
suppression of the markers’ circadian variations. A posi-
tive correlation between mean circadian OC and CTx le-
vels in postmenopausal women was also revealed; the cor-
relation proved significant in AO subjects. Adipose tissue 
distribution-dependent alterations in circadian bone mar-
ker concentrations seen in our obese subjects might have 
been related to changes in osteotropic agents (mainly hor-
mones) frequently observed in obese females [35,36]. It 
has been assumed that the mechanisms actively participa-
ting in the maintenance of bone mineral density in obe-
se individuals, and, in particular, postmenopausal women, 
include hormones, i.e., estrogens, adrenal androgens (de-
hydroepiandrosterone [DHEA] and its sulfate-bound form 
[DHEAS]), leptin and melatonin, and changes in calcium 
Variables
Postmenopausal obese women Control group
GO
WHR <0.8
(n-12) 
AO
WHR ≥0.8
(n-17) 
C
WHR 0.69–0.78
(n-8)
FT (pmol/l)
OC (µmol/l) NS –0.679a � NS
CTx (nmol/l) –0.600a –0.655a NS
OPG (pmol/l) 0.790a 0.801a NS
sRANKL (pmol/l) 0.786a NS ¯  0.560a
OC (µmol/l)
CTx (nmol/l) NS 0.967a � 0.799a
OPG (pmol/l) NS NS 0.854a
sRANKL(pmol/l) NS NS 0.648a
CTx (nmol/l)
OPG (pmol/l) –0.706a NS ¯ 0.754a
sRANKL(pmol/l) –0.650a NS ¯ 0.492a
OPG (pmol/l) sRANKL (pmol/l) 0.824a 0.789a 0.859a
Table 2.  Correlation between mean daily serum concentrations of free testosterone (FT), osteocalcin (OC), C-terminal telopeptide of type I collagen (CTx), 
osteoprotegerin (OPG) and soluble receptor activator of nuclear factor-κB ligand (sRANKL) in postmenopausal obese women with gynoid (GO: WHR 
<0.8) and android distribution of body fat (AO: WHR ≥0.8) and in postmenopausal healthy women with normal body weight (control group − C)
a p≤0.05 – statistically significant values of correlation coefficients; ¯ or � correlation vs GO group.
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ne (GH)/insulin-like growth factor-I (IGF-I) relationships 
[18,21,28,29,30,31,32]. However, the potentially protective 
role of testosterone level changes in reducing postmeno-
pausal bone loss has not been unequivocally accounted for.
Similar to our previous investigations [33], we demonstrated 
adipose tissue distribution-dependent differences in mean 
circadian FT concentrations and/or circadian amplitude va-
riations. It is well established that the peri- and postmeno-
pausal tendency to deposit a disproportionate amount of fat 
in the trunk (abdominal) region is usually associated with 
increased androgen production [4]. A decline in sex hor-
mone-binding globulin (SHBG), characteristic of postme-
nopausal AO women, results in an increase of FT levels; 
the latter, in turn, exerts a stimulating effect on androgen 
receptors in visceral fat, thus increasing the tendency to de-
velop visceral obesity and insulin resistance [35,36,43,44]. 
Our postmenopausal AO subjects demonstrated significant 
elevation of mean circadian FT levels compared to GO and 
control participants. Both obese subgroups showed a decre-
ase in circadian FT amplitude compared to the control gro-
up, although considerably larger differences in the ampli-
tude were found in the GO than in the AO subgroup. This 
influenced circadian OC amplitude variations in our obe-
se subjects compared to the control, since the differences 
in circadian OC variations were also larger in the GO than 
in the AO subgroup. Mean circadian FT levels in women 
with gynoid obesity correlated significantly and negative-
ly only with CTx (although no significant correlation was 
found between OC and CTx), whereas AO subjects sho-
wed a significant negative correlation between FT and OC 
as well as FT and CTx (there was a significant and posi-
tive correlation between OC and CTx). Compared to GO 
participants, those with AO had higher correlation coeffi-
cients. The obtained results seem to confirm that adipose 
tissue distribution-dependent changes in circadian FT le-
vels of postmenopausal women might play a role in altering 
the balance between bone resorption and bone formation.
Although in vitro studies involving bone cell cultures of 
different species have revealed that both testosterone and 
5a-dihydrotestosterone (DHT) directly stimulate the pro-
liferation of osteoblast precursor cells [7], the effect of the 
hormones on osteoblast differentiation has not been ful-
ly elucidated. They may have no influence on or, alterna-
tively, stimulate or inhibit the expression of alkaline pho-
sphatase, type I collagen and OC by osteoblasts, and bone 
matrix mineralization [7]. Most authors believe, however, 
that androgens stimulate osteoblast differentiation and de-
crease osteoblast and osteocyte apoptosis [7]. Androgens 
are capable of exerting both direct and indirect effects on 
bone tissue via the regulation of growth factor and cytokine 
expression [7,13,22]. DHT has been shown to reduce OPG 
levels, which could potentially stimulate osteoclast activi-
ty [16]. Osteoclasts derived from the bone marrow colony-
-forming unit-granulocyte macrophage hematopoietic cell 
lineage undergo proliferation after orchidectomy, presuma-
bly due to androgen deficiency. Osteoclast differentiation 
requires contact with stromal cells of the osteoblastic line-
age in the bone marrow microenvironment, and stimulation 
by RANKL expressed and secreted by osteoblastic cells, 
which binds to RANK on osteoclasts [3,17,46]. The effect 
of RANKL on osteoclasts is regulated by OPG, which acts 
as a specific decoy receptor for RANKL, and inhibits the 
RANKL-RANK pathway through competitive binding to 
RANKL. Thereby, ultimate stages of osteoclastogenesis are 
inhibited and osteoclast activation reduced. Consequently, 
the pool of active osteoclasts becomes limited and bone re-
sorption diminished [3,17,46]. Chen et al. [5] demonstrated 
that testosterone increased OPG mRNA expression in both 
mouse bone-cell cultures and MC3T3-E1 cells, whereas 10–8 
M PTH– (1-34) as well as 10–8 M 1,25(OH)2D3 inhibited OPG 
mRNA expression in mouse bone cells. 10–8 M testosterone 
antagonized OPG mRNA expression inhibited by 10–8 M 
PTH– (1-34), but failed to affect OPG mRNA expression 
inhibited by 10–8 M 1,25(OH)2D3. 10–8 M a-DHT increased 
OPG mRNA expression. On the other hand, testosterone 
did not affect RANKL mRNA expression in MC3T3-E1 
or mouse bone cells. The results indicated that testosterone 
increased OPG mRNA expression in mouse bone-cell cul-
tures and the osteoblastic cell line. These effects are likely 
to occur through the androgen receptor [5]. Other authors 
suggest that testosterone might suppress osteoclast forma-
tion through the inhibition of RANKL and macrophage-co-
lony stimulating factor (M-CSF) [19], which mediates the 
initial stage of osteoclast differentiation. During this sta-
ge, monocyte-macrophage precursor cells acquire sensiti-
vity to RANKL [13,22]. In vitro data indicate that andro-
gens appear to exert their bone protective effects, in part 
directly and in part indirectly, through osteoblastic cells.
In vivo studies concerning relationships between OPG and 
RANKL concentrations, bone metabolism and/or BMD and 
testosterone are scarce and fairly ambiguous. The incon-
sistency of results is largely due to the influence of age on 
OPG levels. Khosla et al. [24] suggest that, in vivo, testo-
sterone decreases OPG levels in normal elderly men, whe-
reas estrogen tends to have the opposite effect. These dif-
ferential effects of estrogen versus testosterone on OPG 
production may explain, at least partially, why testosterone 
has weaker effects than estrogen on inhibiting bone resorp-
tion in vivo in humans. Khosla et al. [23] found no relation-
ship between serum OPG and testosterone in postmenopau-
sal women; however, a weak correlation was observed in 
men below the age of 50. Serum OPG increased with age 
in both men and women. Significantly higher serum levels 
of the osteokine were observed in premenopausal women 
compared to men below the age of 50; no difference was 
seen in postmenopausal women compared with men over 
50 years of age. Our results also did not confirm an asso-
ciation between mean circadian FT and OPG in non-obe-
se postmenopausal participants, whereas we did find a si-
gnificant correlation between mean circadian FT levels and 
sRANKL. Kudlacek et al. [25] observed a sharp increase of 
serum OPG in females after 60 years and in males after 70 
years of age; a significant correlation was found between 
OPG levels in postmenopausal women, and especially tho-
se after the age of 65. Other authors [11,20,45] confirmed a 
significant increase of OPG with age in healthy females and 
males; Trofimov et al. [45] demonstrated a clear positive 
correlation with age in both sexes, but after the age of 40.
Only a few researchers have investigated the relationship be-
tween OPG and bone metabolism in healthy women. Some 
of them did not find any correlation between OPG levels 
and bone markers [11,23,45] as well as between bone mar-
kers and BMD [23,45], while some others [20] did observe 
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not between OPG and BMD. Moreover, their female sub-
jects demonstrated a negative correlation between serum 
OPG and tartrate-resistant acid phosphatase. Our chrono-
biological studies yielded similar results regarding the rela-
tionships between OPG and bone markers in postmenopau-
sal women with normal body weight. Mean circadian OPG 
levels correlated positively and significantly with mean cir-
cadian OC and CTx. A significant positive correlation was 
also seen between sRANKL and mean circadian OC and 
CTx levels, although the associations were weaker compa-
red to those between OPG and the above-mentioned bone 
markers. Untreated patients with established osteoporosis 
evaluated by Fahrleitner-Pammer et al. [11] showed a strong 
relationship between serum OPG and bone markers, i.e., 
OC and CTx. The concentrations of bone resorption mar-
kers decreased after subcutaneous OPG injections in post-
menopausal women and patients with Paget’s disease [2,8].
The lack of detailed multidirectional in vivo studies on the 
associations between testosterone and OPG and RANKL 
concentrations in postmenopausal obese and normal we-
ight women urged us to take a closer look into the issue. 
Our results have revealed that adipose tissue distribution-
-dependent increase in mean circadian FT and suppression 
of OC and CTx in obese postmenopausal women were as-
sociated with 1) a decrease in mean circadian OPG levels 
and 2) a decrease of mean circadian sRANKL (larger in 
the AO compared to GO subgroup). GO participants de-
monstrated a shift of sRANKL rhythm acrophase towards 
later hours, whereas AO subjects showed suppression of 
OPG and sRANKL rhythms. Compared to the control gro-
up, our obese postmenopausal subjects also had signifi-
cant adipose tissue distribution-dependent changes in the 
correlations between 1) mean circadian FT and bone mar-
kers; mean circadian FT and OPG, 2) mean circadian OC 
and CTx, 3) mean circadian OPG and sRANKL, and 4) 
mean circadian CTx and OPG; mean circadian CTx and 
sRANKL. Compared to GO participants, those with AO 
had higher coefficients of correlations between mean cir-
cadian FT and OC as well as between OC and CTx, and 
lower in the case of FT and sRANKL as well as between 
CTx and OPG and CTx and sRANKL.
Based on our findings and literature reports, it seems that 
testosterone may have a positive, partly direct and par-
tly indirect, effect on bone tissue by stimulating OPG 
and/or RANKL expression in osteoblasts and bone mar-
row stromal cells. The indirect effect might be mediated 
through osteoblast-specific receptors as well as via pro-
duction of cytokines and growth factors, which modula-
te OPG and/or RANKL expression. Some of these factors 
can also be secreted by adipose tissue [13,22]. It should 
be noted that testosterone can be metabolized via the cy-
tochrome P450 aromatase enzyme complex into 17b-es-
tradiol [7], which has been shown to regulate the balance 
of the RANKL/RANK/OPG system via specific receptors. 
Estradiol was found to stimulate OPG expression in hu-
man osteoblastic cells via estrogen receptor a [40]. It can 
also indirectly modulate RANKL and/or OPG expression 
through the inhibition of proresorptive cytokines such as 
IL-1, IL-6, TNF-a, M-CSF and PGE2, and stimulation of 
transforming growth factor beta (TGF-b) and IGF-I pro-
duction [13,22,27,40]. Greater changes in circadian OC va-
riations and mean circadian osteokine concentrations in the 
GO compared to AO subgroup might be partially accoun-
ted for by increased estrogen production in gynoid obesity.
To sum up, adipose tissue distribution-dependent increase 
of testosterone secretion in obese women might be among 
the factors of the mechanism protecting against bone loss in 
postmenopausal years. The hormone might exert its effects 
through the interaction of the above-mentioned mechanisms.
conclusions
1.   Postmenopausal obesity results in adipose tissue distri-
bution-dependent alterations in circadian free testostero-
ne levels accompanied by suppression of bone metabo-
lism and a decline in circadian variations of osteokines 
under investigation, especially sRANKL.
2.   Increased FT secretion in postmenopausal women mi-
ght exert a protective effect on bone tissue, most like-
ly via a shift in the OPG/RANKL ratio that tilts the ba-
lance toward a functional excess of OPG.
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